We're Searching for a Way to Live Life Beyond the Mask

If you or your child are experiencing symptoms of COVID‑19 and took a test in the last 3 days, the BLAZE‑1 Study may be an option.

Meeting an Urgent Need with a Unique Study

The BLAZE‑1 Study is testing treatments to prevent mild to moderate COVID‑19 symptoms from becoming severe. COVID‑19 is particularly concerning for people who may be at greater risk of developing severe symptoms. Eli Lilly and Company, a US‑based pharmaceutical company, is conducting the BLAZE‑1 Study to meet this urgent need. The BLAZE‑1 Study aims to learn if one or more investigational medicines could prevent the progression of mild to moderate COVID‑19 to severe COVID‑19.

The BLAZE‑1 Study is for people of all ages who have been tested for COVID‑19 in the last 3 days and are at high risk of developing severe symptoms. If you or your child fit these criteria, you may qualify to participate. Most research sites are offering in‑home appointments to make participation convenient for volunteers. Everyone now enrolling in the BLAZE‑1 Study will receive one or more investigational medicines; no one will receive a placebo.

Are you interested?

Are You Interested?

Only people who have had a COVID‑19 test in the last 3 days may be eligible for the BLAZE‑1 Study. If you or your child have had a COVID‑19 test in the last 3 days, it's important to begin the prequalification process as soon as possible. To do so, click the I'm Interested button and complete the steps that follow.

The Study at a Glance

The BLAZE‑1 Study is available to people of all ages with COVID‑19 symptoms, who took a test to confirm their diagnosis in the last 3 days and are at a greater risk of their symptoms becoming more severe. Most research sites are offering in‑home appointments.

Trial Details

Condition
COVID‑19
Potential Treatments Under Study
One or more monoclonal antibodies

What's Involved?

Maximum Trial Length
About 3 Months
Appointments
Approximately 9 (possibly in‑home)

Who Qualifies?

Gender
All
Ages
All
About the Study Drug

About the Study Drug

The BLAZE‑1 Study is testing whether investigational medicines could prevent the progression of mild to moderate COVID‑19 to severe COVID‑19. The investigational medicines are a common type of drug that scientists make to mimic a part of the body's immune system, but they are not vaccines. Everyone now enrolling in the BLAZE‑1 Study will receive one or more investigational medicines, not a placebo.

Why Participate?

Each person and each research study are different. Every research study has risks and benefits to consider when deciding whether to participate. If you or your child qualify, you and those close to you are the only ones who can decide if participation is the right choice.
You may want to take part in this research study for the following reasons:

Advance Medicine

Move COVID‑19 research forward and help find a treatment that may help others

Become Involved

Take an active role in your or your child's health by staying informed and exploring new options

Access Study Drug

Try one or more investigational medicines for COVID‑19 that are available through this study

Interested in helping us search for a way to live life beyond the mask?

Interested in helping us search for a way to live life beyond the mask?

Copyright © 2021 Eli Lilly and Company

Created by Rebar Interactive